YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

SHSC:1558 Stock Report

Market Cap: HK$8.2b

YiChang HEC ChangJiang Pharmaceutical Past Earnings Performance

Past criteria checks 3/6

YiChang HEC ChangJiang Pharmaceutical's earnings have been declining at an average annual rate of -2.1%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 6% per year. YiChang HEC ChangJiang Pharmaceutical's return on equity is 17.5%, and it has net margins of 29.7%.

Key information

-2.1%

Earnings growth rate

-1.7%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate6.0%
Return on equity17.5%
Net Margin29.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How YiChang HEC ChangJiang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSC:1558 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 245,5401,6481,891360
31 Mar 245,9171,8201,915276
31 Dec 236,2951,9931,939192
30 Sep 235,9781,5661,870190
30 Jun 235,6611,1391,801187
31 Mar 234,7036081,676158
31 Dec 223,745771,551130
30 Sep 222,875-181,324115
30 Jun 222,005-1131,097101
31 Mar 221,459-351990105
31 Dec 21914-588883110
30 Sep 21690-43698698
30 Jun 21467-2851,08987
31 Mar 211,4072771,27890
31 Dec 202,3488391,46892
30 Sep 203,7921,2041,93374
30 Jun 205,2361,5682,39955
31 Mar 205,7301,7432,63427
31 Dec 196,2241,9192,8690
30 Sep 195,1621,5982,3560
30 Jun 194,0991,2761,8430
31 Mar 193,3051,1091,4410
31 Dec 182,5109431,0380
30 Sep 182,4669619680
30 Jun 182,4229808970
31 Mar 182,0128137310
31 Dec 171,6026475650
30 Sep 171,3255574430
30 Jun 171,0484673220
31 Mar 179954243180
31 Dec 169423813140
30 Sep 169043542940
30 Jun 168663272740
31 Mar 167792972360
31 Dec 156932661970
30 Sep 156372361900
30 Jun 155812071830
31 Mar 155111711770
31 Dec 144411351700
31 Dec 13316581410

Quality Earnings: 1558 has a high level of non-cash earnings.

Growing Profit Margin: 1558's current net profit margins (29.7%) are higher than last year (20.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1558's earnings have declined by 2.1% per year over the past 5 years.

Accelerating Growth: 1558's earnings growth over the past year (44.7%) exceeds its 5-year average (-2.1% per year).

Earnings vs Industry: 1558 earnings growth over the past year (44.7%) exceeded the Pharmaceuticals industry 9.4%.

Return on Equity

High ROE: 1558's Return on Equity (17.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 18:55
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Ling ZhangChina Merchants Securities (HK) Co., Ltd
null nullCMB International Securities Limited